Literature DB >> 26804582

Bioavailability study of arsenic and mercury in traditional Chinese medicines (TCM) using an animal model after a single dose exposure.

Ujang Tinggi1, Ross Sadler2, Jack Ng3, Barry Noller4, Alan Seawright3.   

Abstract

Traditional Chinese medicines (TCM) are increasingly being used as alternative medicines in many countries, and this has caused concern because of adverse health effects from toxic metal bioavailability such as mercury (Hg) and arsenic (As). The aim of this study was to investigate the bioavailability of As and Hg from TCM after a single exposure dose using an animal model of female Sprague-Dawley rats. The rats were divided into 6 groups which included four groups treated with sodium arsenite (NaAsO2), arsenic sulfide (As2S3), mercuric chloride (HgCl2), mercuric sulfide (HgS), and two groups treated with TCM containing high Hg or As (Liu Shen Wan: As 7.7-9.1% and Hg 1.4-5.0%; Niuhang Jie du Pian: As 6.2-7.9% and Hg <0.001%). The samples of urine, faeces, kidney and liver were collected for analysis and histological assay. The results indicated that relatively low levels of As and Hg from these TCM were retained in liver and kidney tissues. The levels of As in these tissues after TCM treatment were consistent with the levels from the As sulphide treated group. With the exception of the mercuric chloride treated group, the levels of Hg in urine from other groups were very low, and high levels of As and Hg from TCM were excreted in faeces. The study showed poor bioavailability of As and Hg from TCM as indicated by low relative bioavailability of As (0.60-1.10%) and Hg (<0.001%). Histopathological examination of rat kidney and liver tissues did not show toxic effects from TCM. Crown
Copyright © 2016. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chinese medicines; Rat study; Relative bioavailability; Risk assessment

Mesh:

Substances:

Year:  2016        PMID: 26804582     DOI: 10.1016/j.yrtph.2016.01.010

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  8 in total

1.  Compatibility of Niuhuang Jiedu Tablets Results in Attenuated Arsenic Bioaccumulation and Consequent Protection against Realgar-Induced Toxicity in Mice.

Authors:  Wenfeng Xu; Shuo Xu; Yongmei Kuang; Xiaorong He; Pengfei Jin
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-23       Impact factor: 2.650

2.  Arsenic Accumulation of Realgar Altered by Disruption of Gut Microbiota in Mice.

Authors:  Wenfeng Xu; Shanshan Zhang; Wenqing Jiang; Shuo Xu; Pengfei Jin
Journal:  Evid Based Complement Alternat Med       Date:  2020-08-18       Impact factor: 2.629

Review 3.  Properties of realgar bioleaching using an extremely acidophilic bacterium and its antitumor mechanism as an anticancer agent.

Authors:  Peng Chen; Ruixiang Xu; Lei Yan; Zhengrong Wu; Yan Wei; Wenbin Zhao; Xin Wang; Qinjian Xie; Hongyu Li
Journal:  Biol Res       Date:  2017-05-22       Impact factor: 5.612

4.  Neuroprotective Effects and Hepatorenal Toxicity of Angong Niuhuang Wan Against Ischemia-Reperfusion Brain Injury in Rats.

Authors:  Bun Tsoi; Xingmiao Chen; Chong Gao; Songlin Wang; Sau Chu Yuen; Depo Yang; Jiangang Shen
Journal:  Front Pharmacol       Date:  2019-05-29       Impact factor: 5.810

Review 5.  Minerals in biology and medicine.

Authors:  Oliver W L Carter; Yingjian Xu; Peter J Sadler
Journal:  RSC Adv       Date:  2021-01-06       Impact factor: 3.361

6.  Comparative pharmacokinetics and urinary excretion of arsenic and mercury after oral administration of realgar, cinnabar and AnGongNiuHuang Pill to rats.

Authors:  Xiao Wu; Zeling Zhong; Kuangmin Lin; Xinhe Liu; Zhichao Wu; Zitian Liu; Yongming Li
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

7.  Heavy Metals and Probabilistic Risk Assessment via Pheretima (a Traditional Chinese Medicine) Consumption in China.

Authors:  Xiaohui Xu; Limin Li; Heng Zhou; Qing Hu; Lingling Wang; Qiang Cai; Yin Zhu; Shen Ji
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

8.  Arsenic-Related Health Risk Assessment of Realgar-Containing NiuHuangJieDu Tablets in Healthy Volunteers Po Administration.

Authors:  Xiao Wu; Ruoning Yan; Rong Guan; Yi Du; Yuexin Liu; Shanhu Wu; Song Zhu; Min Song; Taijun Hang
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.